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One of the hallmarks of Alzheimer’s disease is the presence of extracellular diffuse and fibrillar plaques predominantly 
consisting of the amyloid-β (Aβ) peptide. Apolipoprotein E (ApoE) influences the deposition of amyloid pathology through 
affecting the clearance and aggregation of monomeric Aβ in the brain. In addition to influencing Aβ metabolism, increasing 
evidence suggests that apoE influences microglial function in neurodegenerative diseases. Here, we characterize the impact 
that apoE has on amyloid pathology and the innate immune response in APP PS1ΔE9 and APP PS1-21 transgenic mice. We 
report that Apoe deficiency reduced fibrillar plaque deposition, consistent with previous studies. However, fibrillar plaques 
in Apoe-deficient mice exhibited a striking reduction in plaque compaction. Hyperspectral fluorescent imaging using 
luminescent conjugated oligothiophenes identified distinct Aβ morphotypes in Apoe-deficient mice. We also observed a 
significant reduction in fibrillar plaque–associated microgliosis and activated microglial gene expression in Apoe-deficient 
mice, along with significant increases in dystrophic neurites around fibrillar plaques. Our results suggest that apoE is critical 
in stimulating the innate immune response to amyloid pathology.
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Introduction
One of the hallmark pathologies of Alzheimer’s disease (AD) is 
the presence of extracellular deposits of diffuse and fibrillar 
amyloid plaques predominantly consisting of the amyloid-β (Aβ) 
peptide. Aβ-related pathology is accompanied by the clustering 
of microglia around fibrillar plaques, although the molecular 
mechanisms facilitating microglial clustering are still poorly 
understood (Aguzzi et al., 2013). The formation of Aβ plaques 
within the brain parenchyma is influenced by the concentration 
of monomeric forms of Aβ in the interstitial fluid and by other 
proteins in the brain, perhaps most notably apolipoprotein E 
(apoE; Musiek and Holtzman, 2015). ApoE has previously been 
shown to influence the rate of monomeric Aβ clearance from 
the brain interstitial fluid in an isoform-dependent manner and 
to influence the kinetics of amyloid formation in vitro (Bell et 
al., 2007; Deane et al., 2008; Huynh et al., 2017a). Both of these 
characteristics likely contribute to apoE-dependent effects on Aβ 
plaque formation in vivo.
In addition to influencing Aβ metabolism, increasing evi-
dence suggests that apoE may influence the microglial response 
in different ways in the context of neurodegenerative disease. 
ApoE is predominantly expressed by astrocytes but it is strongly 
up-regulated by microglia in the context of Aβ pathology and can 
influence the activation state of microglia (Uchihara et al., 1995; 
Butovsky et al., 2015; Krasemann et al., 2017). The role of microg-
lia in the course of AD remains ambiguous. Recent genetic evi-
dence strongly implicates microglial function in playing a critical 
role in the disease. Variants in microglial-expressed genes, such 
as TREM2 and CD33 alter the risk of developing AD, implicat-
ing the importance of microglia in the onset and progression of 
AD (Naj et al., 2011; Griciuc et al., 2013; Guerreiro et al., 2013; 
Jonsson et al., 2013). Although chronic microglial activation is 
hypothesized to result in neurotoxic inflammatory signaling, 
recent studies have shown that plaque-associated microgliosis 
was negatively correlated with the degree of neuritic dystrophy 
around plaques, suggesting a potential protective role for microg-
lia in response to amyloid plaque formation (Condello et al., 
2015; Heneka et al., 2015). Mouse models of Aβ deposition that 
are haploinsufficient or completely deficient in Trem2 exhibit 
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reduced plaque-associated microgliosis, and Trem2-deficient 
mice exhibit altered plaque morphology and increased neuritic 
dystrophy, suggestive of a role for microglia in shaping the gross 
structure of plaques and reducing plaque-associated toxicity 
(Ulrich et al., 2014; Wang et al., 2015, 2016; Yuan et al., 2016; Jay 
et al., 2017; Song et al., 2017; Ulland et al., 2017).
Previous studies found that genetic deletion of Apoe in amy-
loid-depositing mouse models overexpressing human amyloid 
precursor protein (APP), but not PS1, resulted in a dramatic 
decrease in diffuse plaques and an absence of fibrillar plaque 
formation (Bales et al., 1997; Holtzman et al., 1999, 2000). How-
ever, more recently developed aggressive mouse models of amy-
loid deposition exhibit modest fibrillar amyloid deposition in the 
absence of apoE (Katsouri and Georgopoulos, 2011). The effect 
of the lack of Apoe expression in these mouse models on the tis-
sue response to amyloid pathology is not currently understood 
and provides an opportunity to understand the role of apoE in 
this process. In this study, we characterize the impact that apoE 
has on amyloid pathology and the innate immune response in 
both the APP PS1ΔE9 and APP PS1-21 amyloid-developing mouse 
models. We found that Apoe-deficient mice exhibited reduced 
fibrillar plaque deposition and altered regional distribution of 
plaque pathology within the hippocampus, consistent with pre-
vious studies (Holtzman et al., 1999; Irizarry et al., 2000; Fagan 
et al., 2002). However, fibrillar plaques in Apoe-deficient mice 
exhibited a striking reduction in plaque compaction, and hyper-
spectral fluorescent imaging using luminescent conjugated 
oligothiophenes (LCOs) identified distinct Aβ morphotypes 
in Apoe-deficient mice. We also observed a significant reduc-
tion in plaque-associated microgliosis and activated microglial 
gene expression in Apoe-deficient mice, along with signifi-
cant increases in dystrophic neurites. Our results suggest that 
apart from influencing Aβ plaque formation, apoE facilitates 
plaque-associated microgliosis and limits plaque-associated 
neuronal toxicity.
Results and discussion
ApoE modifies Aβ deposition
Previous studies in human APP transgenic mice, PDA PP and 
Tg2576, found that Apoe deficiency significantly reduced both 
total and fibrillar Aβ deposition (Bales et al., 1997, 1999; Holtzman 
et al., 2000; Irizarry et al., 2000). Therefore, we first assessed 
total Aβ deposition in the cortex and hippocampus of 6-mo-old 
APP PS1 and Apoe−/−;APP PS1 mice using an N-terminal Aβ anti-
body. Surprisingly, we observed significantly more Aβ depo-
sition in the cortex of Apoe−/−;APP PS1 compared with APP PS1 
mice, which was attributable to a significant increase in both 
the number and size of cortical Aβ immunostained plaques in 
the absence of Apoe expression (Fig. 1, A–D). Marked cortical Aβ 
deposition was also observed in 10-mo-old Apoe−/−;APP PS1ΔE9 
mice (Fig. 1 E). The overall cortical plaque burden did not signifi-
cantly differ between APP PS1ΔE9 and Apoe−/−;APP PS1ΔE9 mice; 
however, there was a significant decrease in the number of Aβ 
plaques (Fig.  1, F and G). Interestingly, the average size of Aβ 
plaques was significantly larger in Apoe−/−;APP PS1ΔE9 mice than 
in APP PS1ΔE9 mice, consistent with the effect of apoE on plaque 
size in the APP PS1 model (Fig. 1 H). In agreement with previous 
studies (Bales et al., 1997; Holtzman et al., 2000), we observed a 
marked shift in the regional distribution of Aβ plaques within 
the hippocampus from the molecular layer of the dentate gyrus 
to the hilus (Fig. 1, A and E).
In previous studies, Tg2576 and PDA PP mice deficient in Apoe 
exhibited virtually no true fibrillar amyloid, suggesting that apoE 
is necessary for Aβ to form Aβ containing a β-sheet structure, i.e., 
amyloid (Bales et al., 1997; Holtzman et al., 2000). Given that we 
observed significant levels of Aβ plaque pathology in both APP PS1 
and APP PS1ΔE9 mice in the absence of Apoe, we decided to assess 
whether the fibrillar amyloid burden was significantly altered 
by Apoe deficiency using X-34, which labels amyloid structures 
(Styren et al., 2000). The cortical and hippocampal amyloid bur-
den in both 6-mo-old Apoe−/−;APP PS1 and Apoe−/−;APP PS1ΔE9 
mice was strongly reduced in the absence of apoE compared with 
mice expressing Apoe; however, fibrillar plaques were detectable 
in the absence of Apoe expression in both strains (Fig. 1, I–N). 
Biochemical analysis of cortical tissue from 6-mo-old APP PS1 and 
Apoe−/−;APP PS1 mice revealed decreased levels of insoluble Aβ40 
and Aβ42, consistent with the observed decrease in X-34+ plaque 
pathology (Fig. S1 A). Interestingly, although soluble Aβ40 levels 
were decreased in Apoe−/−;APP PS1 mice, soluble Aβ42 levels were 
slightly but statistically significantly elevated (Fig. S1 B). This 
might reflect the increase in diffuse Aβ pathology observed by 
N-terminal Aβ antibody staining (Fig. 1 A). Western blot anal-
ysis of APP and the APP C99 cleavage fragment did not reveal a 
significant difference in the ratio of C99 to APP, suggesting that 
apoE did not significantly affect APP processing by β-secretase 
(Fig. S1, C and D).
Recent studies indicate that apoE expression influences the 
initiation of fibrillar plaque deposition, but not the subsequent 
growth of amyloid plaques once plaque formation has occurred 
(Huynh et al., 2017b; Liu et al., 2017). This would suggest that 
apoE serves as a catalyst for the folding of Aβ peptides into 
higher-order amyloid/β-sheet conformations. Aβ42 exhibits a 
greater propensity to form amyloid fibrils, and variants in APP, 
PSEN1, or PSEN2 that increase the production of Aβ42 relative 
to shorter Aβ species result in autosomal dominant AD (Musiek 
and Holtzman, 2015). We speculate that the differences we report 
here in Apoe-deficient APP PS1 models compared with earlier 
APP overexpression models stems largely from differences in 
the relative production of Aβ42: Aβ40 in these different strains. 
Tg2576 mice exhibited a roughly 1:5 ratio of Aβ42/Aβ40 in young 
animals, compared with an ∼1:1 ratio in APP PS1 and APP PS1ΔE9 
mice, which likely results in the accelerated development of 
Aβ-deposition in APP PS1 and APP PS1ΔE9 mice and the forma-
tion of amyloid (Jankowsky et al., 2004; Radde et al., 2006). Thus, 
although apoE may catalyze the conversion of Aβ into a fibrillar 
state, high relative generation of Aβ42 may be sufficient for the 
development of some true amyloid even in the absence of apoE.
ApoE regulates amyloid morphology and conformation
We noted that the amyloid plaques in Apoe−/− mice appeared to 
not stain as intensely with X-34 as in Apoe+/+ mice. Given that the 
plaques in Apoe−/−;APP PS1 plaques were larger than plaques in 
APP PS1 mice, we decided to assess the effect of ApoE on plaque 
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morphology. High-resolution confocal imaging of amyloid plaques 
revealed that the gross morphology of the plaque was strikingly 
different in the presence and absence of apoE (Fig. 2 A). Amy-
loid plaques in 6-mo-old APP PS1 and 10-mo-old APP PS1ΔE9 mice 
had a distinct, dense core that was intensely stained with X-34 
(Fig. 2 A). In contrast, plaques in Apoe−/−;APP PS1 and Apoe−/−; 
APP PS1ΔE9 mice contained numerous wispy fibrils, projecting out 
from a loosely defined core (Fig. 2 A). We quantitatively assessed 
Figure 1. Apoe deficiency increases Aβ plaque size but decreases amyloid burden. (A) Representative images of APP PS1 and Apoe−/−;APP PS1 mice stained 
with an N-terminal Aβ antibody. (B) The percentage of cortical area immunopositive for Aβ was increased in Apoe−/−;APP PS1 mice (28.0 ± 1.4%, n = 7 mice) 
relative to APP PS1 (8.8 ± 0.9%, n = 10 mice); t(15) = 12.1, P < 0.0001, Student’s t test. (C) The mean number of plaques was increased in Apoe−/−;APP PS1 mice 
(230.6 ± 6.5, n = 7 mice) relative to APP PS1 (172.8 ± 9.6, n = 9); t(14) = 4.7, P = 0.0003. (D) The mean plaque size was increased in Apoe−/−;APP PS1 mice (1,159 
± 72.9 µm2, n = 7 mice) relative to APP PS1 (555.1 ± 23.2 µm2, n = 10); t(15) = 9.1, P < 0.0001, Student’s t test. (E) Representative images of APP PS1ΔE9 and 
Apoe−/−;APP PS1ΔE9 mice stained with an N-terminal Aβ antibody. (F) The percentage of cortical area immunopositive for Aβ was not significantly different 
between APP PS1ΔE9 (7.0 ± 0.7%, n = 9 mice) and Apoe−/−;APP PS1ΔE9 (5.6 ± 1.0%, n = 7 mice); t(14) = 1.2, P = 0.25, Student’s t test. (G) The number of cortical 
plaques was significantly reduced in Apoe−/−;APP PS1ΔE9 mice (105.2 ± 13.0, n = 7 mice) compared with APP PS1ΔE9 mice (183.5 ± 12.4, n = 9 mice); t(14) = 4.3, P 
= 0.0007, Student’s t test. (H) The mean plaque size was increased in Apoe−/−;APP PS1ΔE9 mice (529.8 ± 48.6 µm2, n = 7 mice) compared with APP PS1ΔE9 mice 
(377.9 ± 18.5 µm2, n = 9 mice); t(14) = 3.2, P = 0.0064, Student’s t test. (I) Representative images of APP PS1 and Apoe−/−;APP PS1 mice stained with X-34. (J) The 
percentage of cortical area stained with X-34 was significantly decreased in Apoe−/−;APP PS1 mice (0.27 ± 0.08, n = 5 mice) compared with APP PS1 (1.2 ± 0.07, 
n = 4 mice); t(7) = 8.411, P < 0.0001, Student’s t test. (K) The percentage of hippocampal area stained with X-34 was significantly decreased in Apoe−/−;APP PS1 
mice (0.18 ± 0.04, n = 4 mice) compared with APP PS1 (0.85 ± 0.1, n = 5 mice); t(7) = 5.9, P = 0.0006, Student’s t test. (L) Representative images of APP PS1ΔE9 
and Apoe−/−;APP PS1ΔE9 mice stained with X-34. (M) The percentage of cortical area stained with X-34 was significantly decreased in Apoe−/−;APP PS1ΔE9 mice 
(0.54 ± 0.11%, n = 7 mice) compared with APP PS1ΔE9 (2.5 ± 0.19%, n = 9 mice); t(14) = 8.0, P < 0.0001, Student’s t test. (N) The percentage of hippocampal area 
stained with X-34 was significantly decreased in Apoe−/−;APP PS1ΔE9 mice (0.12 ± 0.05%, n = 7 mice) compared with APP PS1ΔE9 (2.0 ± 0.15, n = 9 mice); t(14) 
= 10.4, P < 0.0001, Student’s t test. All values given and plotted as mean ± SEM. Bars, 500 µm. **, P < 0.01; ***, P < 0.001.
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these qualitative observations using a shape compactness index 
that takes into account the perimeter and two-dimensional 
area of the plaque and found that Apoe−/−;APP PS1 and Apoe−/−; 
APP PS1ΔE9 mice exhibited a significantly less compact morphol-
ogy (Fig. 2, B and C). We further quantitatively compared plaques 
by assessing the Gini coefficient of pixel intensity for X-34 stain-
ing (Fig. 2, D–F). We found that plaques from Apoe−/−;APP PS1 and 
Apoe−/−;APP PS1ΔE9 mice exhibited a significant decrease in the 
Gini coefficient, consistent with the observed decrease in inten-
sity of the dense X-34+ core of amyloid plaques compared with 
APP PS1 and APP PS1ΔE9 mice (Fig. 2, E and F).
A previous study demonstrated that a combination of two 
LCOs, q-FTAA and h-FTAA, can be used for spectral assignment 
of distinct aggregated Aβ morphotypes (Nyström et al., 2013). 
q-FTAA stains only mature fibrillar Aβ deposits that are also 
recognized by conventional amyloid ligands, such as thiofla-
vin T and X-34, whereas h-FTAA detects a broader subset of 
disease-associated protein aggregates (Klingstedt et al., 2011, 
2013; Nyström et al., 2013; Magnusson et al., 2014). Given the 
stark contrast in amyloid plaque morphology in Apoe−/− mice, 
we stained tissue sections from 6-mo-old Apoe−/−;APP PS1 and 
APP PS1 mice with a mixture of q-FTAA and h-FTAA. Hyperspec-
tral fluorescence imaging revealed distinct staining patterns 
using q-FTAA and h-FTAA dependent on the Apoe genotype. 
For all mice, minor q-FTAA fluorescence was only observed 
in the core of some plaques. In contrast, h-FTAA staining was 
Figure 2. Apoe deficiency alters amyloid morphology and conformation. (A) Representative, high-magnification images of X-34+ plaques from APP PS1 and 
Apoe−/−;APP PS1 mice and APP PS1ΔE9 and Apoe−/−;APP PS1ΔE9 mice. Bars, 10 µm. (B) Significant decrease in the shape compactness of Apoe−/−;APP PS1 mice 
(11.18 ± 0.38, n = 28 plaques) compared with APP PS1 (13.14 ± 0.50, n = 25 plaques); t(51) = 3.2, P < 0.001, Student’s t test. (C) Significant decrease in the shape 
compactness of Apoe−/−;APP PS1ΔE9 (10.12 ± 0.47, n = 29 plaques) compared with APP PS1ΔE9 (15.19 ± 0.44, n = 43 plaques); t(70) = 7.6, P < 0.001, Student’s 
t test. (D) Representative pixel intensity heat maps for APP PS1 and Apoe−/−;APP PS1. Same scale bars as in A. (E and F) The Gini coefficient for pixel intensity 
was decreased in Apoe−/−;APP PS1 mice (0.37 ± 0.02, n = 28 plaques) compared with APP PS1 (0.47 ± 0.01, n = 25 plaques); t(51) = 4.3, P < 0.0001, Student’s t 
test (E) and the Gini coeffecient for Apoe−/−;APP PS1ΔE9 mice (0.26 ± 0.01, n = 29) compared with APP PS1ΔE9 (0.48 ± 0.01, n = 43 plaques); t(70) = 15.53, P < 
0.0001, Student’s t test (F). Values are given and plotted as mean ± SEM. (G) Fluorescence images of Aβ-deposits costained by the tetrameric LCO, q-FTAA 
(blue), and the heptameric LCO, h-FTAA (red). The images are rendered from z-stacks recorded with the dimensions of x = 250 µm (red line), y = 250 µm (blue 
line), and z = 90 µm (green line; bar, 75 µm). (H and I) Fluorescence lifetime images (H) and lifetime decay curves (I) for h-FTAA stained Aβ-deposits in brain 
tissue sections. The color bar represents lifetimes from 300 ps (orange) to 800 ps (blue) and the images are color-coded according to the representative lifetime. 
The fluorescence lifetimes were collected with excitation at 490 nm. Fluorescence decays were collected from 5 to 10 different plaques in tissue sections from 
five individual APP PS1- or Apoe−/−;APP PS1 mice. Bars, 20 µm. **, P < 0.01; ***, P < 0.001.
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much more abundant in the Apoe−/−;APP PS1 mice compared 
with APP PS1 mice (Fig. 2 G). Hence, in accordance with anti-Aβ 
antibody staining, h-FTAA fluorescence displayed a greater 
amount of Aβ deposition in mice lacking Apoe, and these depos-
its are most likely composed of an Aβ morphotype that is only 
detected by h-FTAA.
To examine the difference in Aβ morphotypes further, we 
performed fluorescence-lifetime imaging (FLIM) analysis of 
h-FTAA–stained Aβ deposits. FLIM is a powerful technique that 
can be used to determine both differential states of binding and 
to observe minute variations in ligand–aggregate interactions, 
and differences in fluorescence decays from h-FTAA have previ-
ously been observed from the ligand bound to prion aggregates 
associated with specific prion strains (Magnusson et al., 2014). 
For APP PS1 mice, h-FTAA–stained Aβ deposits displayed fluo-
rescence decays between 350–600 ps, whereas the decays from 
h-FTAA bound to Aβ deposits in Apoe−/−;APP PS1 mice were con-
siderably longer at 400–800 ps (Fig. 2, H and I). Hence, a distinct 
distribution of fluorescence decays was observed for h-FTAA 
depending on the Apoe genotype, suggesting that the lack of apoE 
induces an enrichment of a specific Aβ morphotype.
Decreased plaque-associated microgliosis and activated 
microglial gene expression in Apoe−/−;APP PS1 and 
Apoe−/−;APP PS1ΔE9 mice
Apoe expression is up-regulated in response to amyloid pathol-
ogy and is thought to play a role in the innate immune response 
in the central nervous system. Interestingly, lipidated apoE binds 
to TREM2 in vitro and may be a potential physiological ligand 
mediating TREM2 activation (Atagi et al., 2015; Yeh et al., 2016). 
Given that a lack of Trem2 expression impairs plaque-asso-
ciated microgliosis, we decided to test whether a lack of Apoe 
expression affected the microglial response to amyloid plaques. 
As expected, both 6-mo-old APP PS1 and 10-mo-old APP PS1ΔE9 
mice exhibited pronounced microglial clustering around amy-
loid plaques (Fig. 3, A and C). However, the number of microg-
lia located within 15 or 30 µm of a plaque was significantly 
decreased in both Apoe−/−;APP PS1 and Apoe−/−;APP PS1ΔE9 mice 
(Fig. 3, A–D). The number of microglia located farther than 30 µm 
from a plaque were unaffected by Apoe genotype, suggesting that 
the effect of apoE on microglial function was specific to activated 
microglia around amyloid plaques (Fig. 3, B and D).
To further assess the effect of Apoe deficiency in the context 
of amyloid pathology, we performed RNA sequencing (RNAseq) 
analysis on cortical tissue from 6-mo-old APP PS1 and Apoe−/−; 
APP PS1 mice. Gene-level analysis revealed that 115 genes were 
differentially expressed in APP PS1 and Apoe−/−;APP PS1 mice 
(Fig.  3  E; Table S1). Changes in microglial gene expression in 
amyloid models detected using whole tissue methods may result 
from either the up-regulation of a given transcript at the cellular 
level or an increase in microglial abundance, which, in general, 
positively correlates with amyloid burden (Srinivasan et al., 
2016). Evidence from single-cell RNAseq studies indicates that 
activated microglia around plaques, termed disease-associated 
microglia, exhibit up-regulation of several genes associated 
with lipid metabolism and phagocytosis, including Itgax and 
Cst7, which are significantly down-regulated in Apoe−/−;APP PS1 
mice, consistent with a decrease in plaque-associated microgliosis 
(Fig. 3 G; Table S1; Keren-Shaul et al., 2017). Gene ontology analysis 
of differentially expressed genes found a significant enrichment 
in genes related to the immune system (Table S2), of which the 
vast majority were down-regulated (Fig. 3 E; Table S1). We further 
analyzed cytokine levels at the protein level in the hippocampus of 
6-mo-old APP PS1 and Apoe−/−;APP PS1 mice and observed reduced 
levels of CCL3, consistent with the reduction in CCL3 transcript 
observed by RNAseq (Fig.  3  F). Interestingly there was a trend 
toward elevated TNFα in Apoe−/−;APP PS1 mice (Fig. 3 F). This may 
be attributable to increases in peripheral TNF-α expression in 
Apoe−/− mice, since TNF-α is transported across the blood–brain 
barrier (BBB; Gutierrez et al., 1993; Grainger et al., 2004). Collec-
tively, these data suggest an overall impairment in the microglial 
response to amyloid pathology in Apoe−/− mice.
Increased neuritic dystrophy in Apoe−/−;APP PS1 mice
Emerging data suggest that reductions in plaque-associated 
microgliosis are associated with increases in dystrophic neurites 
around plaques (Condello et al., 2015; Wang et al., 2016; Yuan et 
al., 2016). Previous studies reported a lack of dystrophic neu-
rites in Apoe−/− mice crossed with either the PDA PP or Tg2576 
models (Holtzman et al., 2000). However, as noted above, PDA PP 
and Tg2576 mice developed minimal, if any, fibrillar plaques in 
the absence of apoE. Moreover, accumulations of protofibrillar 
Aβ species within amyloid plaques are spatially associated with 
increases in dystrophic neurites (Condello et al., 2015). Since the 
Apoe−/−;APP PS1 and Apoe−/−;APP PS1ΔE9 mice developed signifi-
cant fibrillar and diffuse plaques, and exhibit significant reduc-
tions in microgliosis, we tested whether these mice exhibited any 
differences in plaque-associated neuronal toxicity. We labeled 
dystrophic neurites with an N-terminal APP antibody (NT-APP) 
and quantified the abundance of NT-APP staining within 30 µm 
of a plaque. (Fig. 4, A and C). The number of dystrophic neur-
ites around plaques was significantly increased in both 6-mo-old 
Apoe−/−;APP PS1 and 10-mo-old Apoe−/−;APP PS1ΔE9 (Fig. 4, B and 
D). This observation is consistent with a role for apoE in facilitat-
ing plaque-associated microgliosis and reducing plaque-associ-
ated neuronal damage.
Final comments and conclusion
Considerable evidence suggests that apoE influences the pro-
pensity of Aβ to aggregate into fibrillar plaques through several 
potential mechanisms, including affecting the rate of Aβ clear-
ance from the brain and the rate of conversion of Aβ monomers 
and oligomers to mature fibrils (Huynh et al., 2017a). However, 
beyond its effect on amyloid, apoE also influences diverse pro-
cesses in the brain, such as synaptogenesis, phagocytosis, BBB 
function, and microglial activation (Mauch et al., 2001; Bell et 
al., 2012; Butovsky et al., 2015; Chung et al., 2016; Krasemann et 
al., 2017; Shi et al., 2017). The histological and gene expression 
data presented in this study suggest that apoE not only affects 
the structure and level of amyloid pathology, but also the innate 
immune response to amyloid plaques, which in turn may protect 
against plaque-associated neurotoxicity. This observation sup-
ports a role for apoE downstream of plaque-deposition in regu-
lating the toxicity and immune response to amyloid pathology. 
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The influence of apoE on microglial activation may have import-
ant implications for apoE-modulating therapies in AD.
One limitation of the current study is that we did not exam-
ine the potential contribution of apoE-dependent vascular BBB 
changes on plaque deposition or the immune response. Previ-
ous studies indicate that Apoe−/− mice have age-dependent BBB 
dysfunction, which leads to extravasation of peripheral proteins 
with neurotoxic consequences (Hafezi-Moghadam et al., 2007; 
Bell et al., 2012). Moreover, a compromised BBB could lead to 
increased infiltration of peripheral macrophages and neutrophils 
into the brain, which may also be neurotoxic (Zenaro et al., 2015). 
Conceivably, the increase in dystrophic neurites we observe in 
Apoe−/− could be promoted in part by infiltrating neutrophils or 
a compromised BBB. In addition, we cannot exclude the possi-
bility that overexpression of APP and PS1 may also influence the 
phenotypes we report here. Future studies using APP knock-in 
mice that test whether Apoe-dependent alterations in the BBB 
affect microgliosis, plaque burden, and neuritic dystrophy could 
Figure 3. Decreased plaque-associated microgliosis in Apoe-deficient mice. (A) Representative images of APP PS1 and Apoe−/−;APP PS1 mice stained with 
Iba1 to label microglia and X-34 to label amyloid plaques. (B) Significant reduction in the number of microglia in Apoe−/−;APP PS1 (0.60 ± 0.04, n = 7 mice) mice 
compared with APP PS1 (1.7 ± 0.12, n = 7) within 15 µm (t[12] = 8.3, P < 0.0001) and 30 µm (2.5 ± 0.18, n = 7 mice versus 4.5 ± 0.28, n = 7 mice); t(12) = 5.9, P < 
0.0001, Student’s t test. The number of microglia >30 µm from a plaque in APP PS1 (154.3 ± 7.1, n = 7 mice) compared with Apoe−/−;APP PS1 (150.7 ± 14.9, n = 
7 mice) was not significantly different; t(12) = 0.22, P = 0.83, Student’s t test. (C) Representative images of APP PS1ΔE9 and Apoe−/−;APP PS1ΔE9 mice stained 
with Iba1 and X-34. (D) Significant reduction in the number of microglia within 15 µm of Apoe−/−;APP PS1ΔE9 (1.2 ± 0.17, n = 7 mice), compared with APP PS1ΔE9 
(2.2 ± 0.1, n = 11 mice); t(16) =5.6, P < 0.0001, Student’s t test, and within 30 µm (2.8 ± 0.24, n = 7 mice) compared with (4.6 ± 0.16, n = 11 mice); t(16) = 6.5, 
P < 0.0001, Student’s t test. The number of microglia >30 µm from a plaque in APP PS1ΔE9 (160.3 ± 14.7, n = 11 mice) and Apoe−/−;APP PS1ΔE9 (133.2 ± 8.5, n 
= 7 mice) were not significantly different; t(16) = 1.4, P = 0.19, Student’s t test. (E) Selected differentially expressed inflammatory gene expression from APP 
PS1 (n = 6 mice) and Apoe−/−;APP PS1 mice (n = 7 mice). See Table S1 for p-values. (F) Analysis of cytokine levels in the hippocampus of APP PS1 and Apoe−/−; 
APP PS1 mice. Apoe−/−;APP PS1 mice (n = 13 mice) exhibited a significant reduction in CCL3 compared with APP PS1 mice (n = 11 mice). P < 0.0001, Student’s t 
test. Bars, 100 µm. ***, P < 0.001.
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provide additional insight into potential mechanisms underlying 
our observations (Saito et al., 2014).
In addition to BBB dysfunction, Apoe−/− mice develop hyper-
cholesterolemia and atherosclerosis, which are accompanied by 
immune responses to atherosclerotic plaques (Zhou et al., 1996). 
Interestingly, the background strain can strongly influence the 
degree of atherosclerosis that develops in Apoe−/− mice; C57BL/6 
mice exhibit more robust atherosclerosis pathology than C3H 
mice (Su et al., 2006). We observed an increase in the number 
of Aβ-immunoreactive plaques in Apoe−/−;APP PS1 mice, which 
are on a C57BL/6 background, and a decrease in the number of 
Aβ-immunoreactive plaques in Apoe−/−;APP PS1ΔE9 mice, which 
are on a mixed C57BL/6;C3H background. Whether the degree 
of vascular pathology contributed to this dichotomous result is 
unknown, and it is important to note that in addition to back-
ground strain and PSEN1 mutations, the APP PS1 and APP PS1ΔE9 
mice also differ in the promoter used for transgene expression 
(Thy1 vs. Prp, respectively). Overall, the different effects of 
Apoe−/− on Aβ burden we describe in APP PS1 and APP PS1ΔE9 
suggest that the choice of Aβ-deposition model can strongly 
influence the effect of gene KO on Aβ pathology. It is important 
to note that despite the differing effects on Aβ pathology, we 
observed consistent effects of Apoe-deficiency on fibrillar Aβ 
deposition, microgliosis, and neuritic dystrophy in both APP PS1 
and APP PS1ΔE9 models.
ApoE expression is up-regulated in AD, which is generally 
attributed to a proinflammatory response to Aβ pathology. 
Within the brain, apoE is predominantly expressed by astro-
cytes, although microglia, particularly in an activated state, also 
produce apoE (Zhao et al., 2018). The relative contribution of 
microglial and astrocyte-derived apoE to the regulation of Aβ 
deposition and microgliosis is unclear. Microglia immunoreac-
tive for apoE were noted to be intimately associated with senile 
plaques, in contrast to astrocytes, which were localized more 
distally to plaques. The proximity of microglia versus astrocytes 
to plaques could indicate a unique role for microglial expressed 
apoE in the immune response to AD pathology (Uchihara et al., 
1995). Investigations into the effects of apoE on plaque-associ-
ated microgliosis have focused largely on apoE isoform–depen-
dent effects. ApoE4 and apoE2 exhibited increased numbers 
of plaque-associated microglia within certain cortical regions 
of 5xFAD mice compared with apoE3 (Rodriguez et al., 2014). 
Figure 4. Significant increase in plaque-associated neuritic dystrophy in Apoe-deficient mice. (A) Representative image of dystrophic neurites labeled 
with APP (green) and amyloid labeled with X-34 (red). Nuclei are labeled with Topro-3 (blue). (B) Significant increase in the number of dystrophic neurites 
per plaque in Apoe−/−;APP PS1 mice (7.3 ± 0.66, n = 40 plaques) compared with APP PS1 (5.5 ± 0.39, n = 95 plaques); t(133) = 2.48, P = 0.01, Student’s t test. 
(C) Representative image of neuritic dystrophy in APP PS1ΔE9 and Apoe−/−;APP PS1ΔE9 mice. (D) Significant increase in the number of dystrophic neurites per 
plaque in Apoe−/−;APP PS1ΔE9 mice (8.2 ± 0.86, n = 27 plaques) compared with APP PS1ΔE9 (4.5 ± 0.42, n = 26 plaques); t(51) = 3.8, P = 0.0004, Student’s t test. 
All values given and plotted as mean ± SEM. Bars, 20 µm. **, P < 0.01; ***, P < 0.001.
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However, the APOE4 allele did not appear to affect the magnitude 
of plaque-associated microgliosis in human AD patients (Serrano-
Pozo et al., 2013). ApoE expression in general has been shown to 
have pleiotropic effects on microglia and the broader immune 
response. ApoE expression is low in microglia in a homeostatic 
activation state, but is strongly up-regulated by neurodegenera-
tive insults (Butovsky et al., 2014, 2015; Krasemann et al., 2017). 
Moreover, application of recombinant apoE to cultured microglia 
is sufficient to polarize gene expression away from a resting state 
toward a more activated phenotype (Butovsky et al., 2015). This 
suggests that apoE is a powerful modulator of microglial pheno-
type, in agreement with our current findings. In addition, the 
influence of apoE on microglial physiology does not appear to be 
specific to amyloid pathology. Reductions in microgliosis were 
also observed in the experimental autoimmune encephalomy-
elitis model of multiple sclerosis and reduced inflammation and 
neurodegeneration were observed in an Apoe-deficient model of 
tauopathy (Shin et al., 2014; Shi et al., 2017).
The function of plaque-associated microgliosis remains 
poorly understood. Some recent studies may indicate that micro-
gliosis around plaques may initially have a neuroprotective role. 
Plaque-associated dystrophic neurites appear in areas devoid of 
microglial coverage, suggesting that microglia may limit amyloid 
toxicity in plaque-adjacent neurons (Condello et al., 2015). An 
alternative interpretation is that a reduction in plaque-associ-
ated microglia could hamper phagocytic clearance of injured 
dystrophic neurites, resulting in an apparent increase in neu-
ritic dystrophy. ApoE isoforms can differentially influence the 
phagocytosis of synapses by astrocytes and the amount of C1q 
deposition in aging (Chung et al., 2016). Thus Apoe expression, 
either by astrocytes or microglia, may promote the clearance of 
damaged neurites around plaques. Future studies investigat-
ing cell type–specific expression of apoE or inhibition of apoE 
expression following plaque deposition could provide insight 
into the mechanistic basis by which apoE influences the innate 
immune response in the context of amyloid pathology.
Materials and methods
Mice
APP PS1-21 (APP PS1) transgenic mice on a C57BL6 back-
ground containing the APP KM670/671NL Swedish mutations 
and PSEN1 L166P mutation (gift from M. Jucke, University 
of  Tübingen, Tübingen, Germany; Radde et al., 2006) were 
crossed with Apoe−/− mice on a C57BL6 background (Jackson 
Labs) to produce Apoe+/−;APP PS1 mice. Apoe+/−;APP PS1 mice 
were then bred with Apoe+/+ or Apoe−/− mice to produce APP PS1 
or APOE−/−;APP PS1 mice. APP PS1ΔE9 (APP PS1;ΔE9) trans-
genic mice on a C3B6 background (Jackson Labs) containing 
the APP KM670/671NL Swedish mutations and PSEN1 exon 9 
deletion were similarly crossed with Apoe−/− mice to produce 
Apoe+/−;APP PS1ΔE9 mice. Apoe+/−;APP PS1ΔE9 mice were then 
bred to either Apoe−/− or C57BL6 mice to produce Apoe−/−; 
APP PS1ΔE9 or APP PS1ΔE9 mice on a mixed C57BL6;C3B6 
background. APP PS1 mice were analyzed at 6 mo of age and 
APP PS1ΔE9 mice were analyzed at 10 mo of age. All experi-
mental procedures relating to animal use were approved by 
the Washington University Institutional Animal Care and 
Use Committee.
Brain sample collection
Mice were anesthetized with intraperitoneal 200-mg/kg injec-
tions of pentobarbital and perfused with ice-cold PBS containing 
0.3% Heparin. One hemibrain was fixed in 4% paraformaldehyde 
overnight at 4°C followed by storage in a 30% sucrose in PBS (pH 
7.4) solution at 4°C. The other hemibrain was dissected and flash 
frozen for further analysis and stored at −80°C.
Histological analysis
Fixed hemibrains were frozen and serial 50-µm coronal sections 
were obtained from the rostral to caudal end using a sliding 
microtome. Sections were stored in a cryoprotectant solution 
(30% ethylene glycol, 15% sucrose, and 30 mM phosphate) and 
stored at −20°C. Three 50-µm sections spaced 300 µm apart were 
used for each staining procedure.
Amyloid plaque staining and morphology
To visualize Aβ plaques, APP PS1 and Apoe−/−;APP PS1 mice were 
immunostained using the anti-Aβ1-5 antibody 3D6 (gift from Eli 
Lilly, Lilly Corporate Center, Indianapolis, IN), whereas immu-
nostaining for APP PS1ΔE9 and Apoe−/−;APP PS1ΔE9 mice was 
performed with the anti-Aβ1-13 antibody HJ3.4. All sections were 
free-floating and were first treated with 0.3% hydrogen perox-
ide, blocked in 3% milk + 0.25% Triton X-100 in Tris-buffered 
saline (TBS), and then incubated overnight in biotinylated 3D6 
or HJ3.4 accordingly at 4°C. Sections were then developed using 
a Vectastain ABC Elite kit (1:400; Vector Labs), followed by incu-
bation in a 0.025% 3,3′-diaminobenzidine (DAB; Sigma-Aldrich) 
+ 0.01% NiCl + 0.015% hydrogen peroxide solution. Images of 
the stained sections were obtained using a slide scanner (Nano-
Zoomer; Hamamatsu Photonics), exported using NDP Viewer 
(Hamamatsu Photonics), and analyzed using ImageJ software 
(National Institutes of Health). To identify fibrillar plaques, 
free-floating sections from the APP PS1, Apoe−/−;APP PS1, 
APP PS1ΔE9, and Apoe−/−;APP PS1ΔE9 mice were all permeabi-
lized with 0.25% Triton X-100 in PBS and stained with 10 µM 
X-34 in 40% ethanol + 0.02M NaOH in PBS. X-34 images were 
obtained with an Eclipse 80i microscope (Nikon) equipped with 
a digital complementary metal-oxide semiconductor camera 
(ORCA-Flash4.0 V2; Hamamatsu Photonics) and analyzed using 
ImageJ software to determine fibrillar plaque levels.
To determine fibrillar plaque morphology, z-stacked images 
were taken every 0.75 µm from X-34–stained sections. Images 
were acquired on a confocal microscope (A1R+; Nikon) at 40× 
magnification with 1.5× digital zoom. Max intensity projections 
of the z-stack images were then used to assess shape compact-
ness, average intensity, and intensity Gini coefficient. A blurring 
filter was first applied to images to clarify the plaque from back-
ground. All pixels >2× background were considered part of the 
plaque, whereas pixels <1.5× background were considered non-
plaque. Pixels between 1.5 and 2× backgrounds were assigned 
based on edge detection. Average intensity was determined based 
on plaque pixels. Gini coefficient was based on the distribution 
of pixel intensity for plaque pixels. Shape compactness was 
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determined as the ratio of plaque area pixels to plaque perimeter 
pixels after scaling plaques to be the same overall area.
Aβ ELI SA
Cortical tissues from 6-mo-old APP PS1 and Apoe−/−;APP PS1 mice 
were hand-homogenized in 10-fold volume PBS using a Teflon 
pestle. Brain homogenates were spun at 14,000 g for 30 min, and 
the supernatant was retained as the soluble fraction. The pellet 
was resuspended in 10-fold volume 5 M guanidine, hand homog-
enized, and rotated for 3 h at room temperature. Homogenates 
were clarified by centrifugation at 14,000 g for 30 min, and the 
supernatant was retained as the insoluble fraction. Aβ40 and Aβ42 
concentrations were measured by sandwich ELI SA. Aβ40 con-
centration was measured using HJ2 as the capture antibody and 
biotinylated HJ5.1 as the detection antibody. Aβ42 was measured 
using HJ7.4 as the capture antibody and biotinylated HJ5.1 as 
the detection antibody. ELI SAs were developed using streptavi-
din-PolyHRP40 (Fitzgerald) and TMB Superslow reagent (Sigma 
Aldrich). Aβ40 and Aβ42 values were normalized to wet weight 
of brain tissue.
Western blotting
Hippocampal tissue was homogenized in 10-fold volume lysis 
buffer (10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 1% Triton X-100, 
0.1% SDS, and 150 mM NaCl), and lysate was clarified by centrif-
ugation at 15,000 g at 4°C. Total protein concentrations in lysate 
were quantified using a BCA assay, and 50 µg of protein were 
loaded onto a 4–20% Bis-Tris SDS-PAGE gel followed by trans-
fer to nitrocellulose. Full-length APP was detected using 6E10 
(1:1,000; Biolegend), and C99 fragment was detected using 82E1 
(1:1,000; IBL America). Protein detection was visualized using an 
HRP-coupled anti–mouse secondary antibody (1:5,000) and ECL 
reagent. Images of the blot were captured using a G Box (Syn-
Gene) and analyzed in ImageJ.
Cytokine assessment
Levels of IL1β, IL-10, TNF-α, CCL3, CCL2, and CCL4 were assessed 
using a Milliplex multianalyte profiling kit (Millipore) per the 
manufacturer’s instructions. Assays were run on a FlexMAP 
3D (Luminex) at the Andrew M. and Jane M. Bursky Center for 
Human Immunology & Immunotherapy Programs at Washing-
ton University, St. Louis, MO. Cytokine levels were normalized 
for total protein content in lysate as calculated by BCA assay.
LCO staining and fluorescence microscopy
The synthesis of the LCOs, q-FTAA, and h-FTAA have been 
reported previously (Klingstedt et al., 2011), and the LCOs were 
dissolved in deionized water to a final concentration of 1.5 mM. 
Floating sections from 6-mo-old APP PS1 or Apoe−/−;APP PS1 mice 
were equilibrated in PBS and stained with a mixture of 2.4 µM 
q-FTAA and 0.77 µM h-FTAA in PBS or 0.77 µM h-FTAA in PBS for 
30 min (Nyström et al., 2013). After washing in incubation buffer 
the sections were transferred to glass slides and mounted with 
mounting media (DAKO; Agilent). The mounting medium was 
allowed to solidify overnight before the rims were sealed with 
nail polish. The LCO-stained sections were analyzed with a con-
focal laser scanning microscope (LSM 780; Zeiss) equipped with 
a 32-channel spectral array detector (QUA SAR GaAsP; Zeiss) and 
a tunable In Tune laser (488–640 nm; Zeiss), as well as a modu-
lar FLIM system (Becker and Hickl). In spectral mode, q-FTAA 
and h-FTAA were excited with a 458-nm laser, and the emitted 
light was detected in steps of 8.7 nm from 488 to 686 nm. Z-stacks 
were recorded with the dimension of x = 250 µm, y = 250 µm, and 
z = 90 µm using a Plan-Apochromat 20×/0.8 M27, and three-di-
mensional images were generated by spectral mixing using the 
ZEN2010 software. Three-dimensional images were rendered by 
spectral unmixing using the ZEN2010 software. For the FLIM, 
the emitted photons were routed through the direct coupling 
confocal port of a scanning unit (LSM 780; Zeiss) and detected 
by a hybrid detector (HPM-100-40; Becker and Hickl). Data were 
recorded by a Simple-Tau 152 system (SPC-150 TCS PC FLIM mod-
ule; Becker and Hickl) with the instrument recording software 
SPCM version 9.42 (Becker and Hickl) in the FIFO image mode, 
256 × 256 pixels, using 256 time channels (Becker and Hickl). 
For all acquisitions, a main beam splitter (T80/R20; Zeiss) was 
used and the pinhole was set to 20.2 µm. Scanning area was set 
to 235.7 × 235.7 µm, with a scanning resolution of 512 × 512 pix-
els. Furthermore, a Plan-Apochromat 40×/1.3 Oil DIC objective 
lens was used, and a 510-nm long pass filter was positioned in 
front of the hybrid PMT. Excitation used the 490-nm laser line 
from the pulsed tunable In Tune laser with a repetition rate of 
40 MHz. Data were subsequently analyzed in SPCImage version 
3.9.4 (Becker and Hickl), fitting each of the acquired decay curves 
to a triexponential function, and color-coded images showing the 
intensity-weighted mean lifetimes were generated with the same 
software. Fluorescence decays were collected from 5–10 different 
plaques in tissue sections from five individual 6-mo-old APP PS1 
or Apoe−/−;APP PS1 mice.
Microglia, dystrophic neurites, and fibrillar plaque staining
To assess microglial colocalization with fibrillar plaques, sec-
tions from each group of mice were costained with X-34 and 
Iba-1. Free-floating sections were first stained with X-34 fol-
lowed by blocking, using 3% normal donkey serum in TBS and 
then incubation with rabbit anti–Iba-1 (1:10,000; Wako) + 1% 
donkey serum in TBS overnight at 4°C. Iba-1–stained sections 
were then incubated in secondary donkey anti–rabbit Alexa 
Fluor 647 (1:1000; Thermo Fisher) in PBS. Neuritic dystrophy 
around fibrillar plaques was assessed in each group of mice 
using 22C11, an antibody to the N terminus of APP, and the X-34 
dye. Free-floating sections were blocked in confocal buffer (0.5% 
BSA, 2% goat serum, and 0.15% Triton X-100 in PBS) and then 
incubated with 22C11 (1:2,000; Millipore) in confocal buffer 
overnight at 4°C. Sections were then incubated in confocal buffer 
with biotinylated goat anti–mouse IgG1 (1:2,000; Thermo Fisher) 
followed by Streptavidin-488 (1:2,000; Thermo Fisher) + To-Pro3 
(nuclear stain, 1:1,000; Thermo Fisher) in PBS.
Confocal analysis
Confocal images were taken in the cortical regions of the Iba-
1/X-34– and APP/X-34–stained sections using a confocal micro-
scope (A1R+; Nikon). Z-stacked images were acquired every 1.25 
µm at a 20× magnification. Images were then analyzed using 
Imaris software (Bitplane) or ImageJ. For all Imaris analyses, 
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the Spots and Surfaces functions were used. The coordinates 
of microglia and the location and volume of Aβ plaques were 
identified using the Spots and Surfaces functions, respectively, 
and imported into Matlab (Mathworks). The number of microg-
lia within a 15- and 30-µm radius were then determined using 
an automated script. The level of APP accumulation in neuritic 
processes surrounding X-34 plaques for APP PS1 and Apoe−/−; 
APP PS1 mice was determined by creating Spots for APP and Sur-
faces for X-34. The volume and number of APP-NT+ neuritic pro-
cesses was determined within 30 µm using an automated script. For 
APP PS1ΔE9 and Apoe−/−;APP PS1ΔE9 mice the level of APP around 
X-34 plaques was determined by creating surfaces for both 
APP and X-34. The Dilate Xtension was used to dilate out the 
X-34 plaque surface 15 µm and create a second dilated surface. 
To determine the volume of APP surface within 15 µm of X-34 
plaque, surface–surface colocalization Xtension was run using 
the dilated surface and APP surface as the two surfaces for com-
parison. The number and volume of APP-NT+ neurites per plaque 
was found and determined based on overall X-34 plaque volume.
RNAseq analysis
RNA was extracted from frozen cortex tissue of 6-mo-old 
APP PS1 and Apoe−/−;APP PS1 mice using TRIzol per the manufac-
turer’s instructions. Isolated RNA was then treated with DNase 
to remove any contaminating genomic DNA and RNA integrity 
assessed using a Bioanalyzer 2100 (Agilent) to ensure an RNA 
integrity number >7. Library preparation was performed using 
the SMA RTer RNA kit (Clontech), and libraries were sequenced 
on a HiSeq2500. Sequence data were aligned to the mouse refer-
ence genome mm10 using STAR. Gene-level differential expres-
sion analysis was performed in Partek Genomic Suite. Gene 
ontology enrichment analysis was performed in Partek Genomic 
Suite by comparing the list of differentially expressed genes with 
the gene ontology database using a Fisher’s exact test. All data 
have been deposited at GEO (accession no. GSE109906).
Statistical analysis
Statistical significance between two groups was assessed by two-
tailed, unpaired Student’s t test with significance assigned for P 
< 0.05. Statistical analysis of differential gene expression from 
RNAseq data were assessed using Partek Genomic Suite. A cor-
rected p-value of 0.05 following Benjamini-Hochberg correction 
for multiple comparisons was considered statistically significant.
Online supplemental material
Fig. S1 shows that 6-mo-old Apoe−/−;APP PS1 mice exhibit reduced 
insoluble levels of Aβ40 and Aβ42 compared with APP PS1 mice. Table 
S1 presents the list of genes that were differentially expressed in the 
cortex of 6-mo-old Apoe−/−;APP PS1 and APP PS1 mice with a P < 0.05 
following false discovery rate correction. Table S2 presents the top 
10 gene ontology functions identified for differentially expressed 
genes in Apoe−/−;APP PS1 and APP PS1 mice.
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